MXPA05010159A - Uso de inhibidores de trombina de bajo peso molecular, en terapia para disminuir el colesterol. - Google Patents

Uso de inhibidores de trombina de bajo peso molecular, en terapia para disminuir el colesterol.

Info

Publication number
MXPA05010159A
MXPA05010159A MXPA05010159A MXPA05010159A MXPA05010159A MX PA05010159 A MXPA05010159 A MX PA05010159A MX PA05010159 A MXPA05010159 A MX PA05010159A MX PA05010159 A MXPA05010159 A MX PA05010159A MX PA05010159 A MXPA05010159 A MX PA05010159A
Authority
MX
Mexico
Prior art keywords
cholesterol
molecular weight
low molecular
lowering therapy
thrombin inhibitors
Prior art date
Application number
MXPA05010159A
Other languages
English (en)
Spanish (es)
Inventor
Grind Margaretha
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05010159A publication Critical patent/MXPA05010159A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
MXPA05010159A 2003-03-22 2004-03-19 Uso de inhibidores de trombina de bajo peso molecular, en terapia para disminuir el colesterol. MXPA05010159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0306615.6A GB0306615D0 (en) 2003-03-22 2003-03-22 New use
PCT/SE2004/000417 WO2004082702A1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Publications (1)

Publication Number Publication Date
MXPA05010159A true MXPA05010159A (es) 2005-11-16

Family

ID=9955311

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010159A MXPA05010159A (es) 2003-03-22 2004-03-19 Uso de inhibidores de trombina de bajo peso molecular, en terapia para disminuir el colesterol.

Country Status (17)

Country Link
US (1) US20060183692A1 (https=)
EP (1) EP1608311B1 (https=)
JP (1) JP2006520813A (https=)
KR (1) KR20050114237A (https=)
CN (1) CN1761479A (https=)
AT (1) ATE475417T1 (https=)
AU (1) AU2004222409B2 (https=)
BR (1) BRPI0408522A (https=)
CA (1) CA2517191A1 (https=)
DE (1) DE602004028348D1 (https=)
ES (1) ES2346969T3 (https=)
GB (1) GB0306615D0 (https=)
MX (1) MXPA05010159A (https=)
NO (1) NO20054285L (https=)
NZ (1) NZ542505A (https=)
WO (1) WO2004082702A1 (https=)
ZA (1) ZA200507614B (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237518B (it) * 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
AU714985B2 (en) * 1996-04-23 2000-01-13 Merck & Co., Inc. Pyrazinone thrombin inhibitors
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
WO2004082702A1 (en) 2004-09-30
KR20050114237A (ko) 2005-12-05
WO2004082702A8 (en) 2005-03-24
ES2346969T3 (es) 2010-10-22
CA2517191A1 (en) 2004-09-30
GB0306615D0 (en) 2003-04-30
NO20054285L (no) 2005-10-20
ZA200507614B (en) 2006-06-28
NO20054285D0 (no) 2005-09-16
DE602004028348D1 (de) 2010-09-09
US20060183692A1 (en) 2006-08-17
BRPI0408522A (pt) 2006-03-07
EP1608311B1 (en) 2010-07-28
NZ542505A (en) 2009-01-31
HK1084329A1 (en) 2006-07-28
AU2004222409B2 (en) 2007-03-08
AU2004222409A1 (en) 2004-09-30
CN1761479A (zh) 2006-04-19
EP1608311A1 (en) 2005-12-28
ATE475417T1 (de) 2010-08-15
JP2006520813A (ja) 2006-09-14

Similar Documents

Publication Publication Date Title
WO2002028379A3 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
DK1216038T3 (da) Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
NO20080855L (no) Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
GEP20094601B (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2002009814A3 (en) New use of lipase inhibitors
NO20084187L (no) Medikamenter og proteiner
GB0002336D0 (en) Medicaments
MY128061A (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
WO2005016249A3 (en) Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
MX2007006279A (es) Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
MXPA05010159A (es) Uso de inhibidores de trombina de bajo peso molecular, en terapia para disminuir el colesterol.
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2009010810A3 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
MX2009003384A (es) Agente terapeutico y/o de mejoramiento para la coagulacion intravascular diseminada.
WO2006026604A3 (en) Methods for promoting wound healing
IL181183A0 (en) Enzyme inhibitor in leukemia
SE9904483D0 (sv) New use
SI1648413T1 (sl) Farmacevtski sestavki kratko delujočega sedativnega hipnotičnega sredstva

Legal Events

Date Code Title Description
FA Abandonment or withdrawal